ProQR Therapeutics announced it has completed a transaction divesting late stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Thea. “Following previous announcements related to this transaction, we are pleased to share that we have now completed the divestment of the sepofarsen and ultevursen programs to Thea, who will continue the development of these potentially transformational therapies for patients with LCA10 and Usher Syndrome,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “We look forward to continuing to advance our Axiomer RNA editing platform, with an initial focus on targets for cholestatic and cardiovascular diseases, as we seek to develop a new class of therapies for patients with high unmet need.” Under the terms of the agreement, ProQR has received an initial payment of EUR 8M and may be eligible for up to EUR 165M in further development, regulatory, and commercial earn-out payments upon related achieved milestones, as well as double-digit royalties based on commercial sales in the US and EU.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRQR:
- ProQR Therapeutics upgraded to Buy from Neutral at Chardan
- ProQR Therapeutics reports Q3 EPS (EUR 0.07) vs (EUR 0.33) last year
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Therapeutics announces strengthened IP with new U.S. patent
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing